Drug Profile


Alternative Names: 14-O-phosphonooxymethyltriptolide-disodium-salt; Minnelide; Minnelide-001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Minnesota
  • Developer Barts and The London NHS Trust; Minneamrita Therapeutics; Queen Mary University of London; Translational Genomics Research Institute
  • Class Antineoplastics; Diterpenes; Epoxy compounds; Phenanthrenes; Phosphoric acid esters
  • Mechanism of Action HSP70 heat shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I Solid tumours
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 20 Nov 2017 Minneamrita Therapeutics LLC plans a phase I trial for Acute Myeloid Leukemia in USA in April 2018 (NCT03347994),
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Late-stage disease) in USA (IV, Infusion)
  • 10 Oct 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03129139)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top